David R Strong1, Sean P David2, Elaine C Johnstone3, Paul Aveyard4, Michael F Murphy5, Marcus R Munafò6. 1. Department of Family and Preventive Medicine, University of California, San Diego, CA; dstrong@ucsd.edu. 2. Center for Education and Research in Family and Community Medicine, Division of General Internal Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA; 3. Department of Oncology, University of Oxford, Oxford, UK; 4. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; 5. Childhood Cancer Research Group, University of Oxford, Oxford, UK; 6. MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK; UK Centre for Tobacco and Alcohol Studies and School of Experimental Psychology, University of Bristol, Bristol, UK.
Abstract
INTRODUCTION: Rates of obesity are higher among more dependent smokers and 37%-65% of smokers seeking cessation treatment are overweight or obese. Overweight or obese smokers may possess metabolic and neurobiological features that contribute to difficulty achieving cessation using front-line nicotine replacement products. Attention to factors that facilitate effective cessation treatment in this vulnerable population is needed to significantly reduce mortality risk among overweight and obese smokers. METHOD: This secondary analysis of 2 large trials of transdermal nicotine replacement in general medical practices evaluated the hypothesis that higher body mass index (BMI) would moderate the efficacy of the nicotine patch. We examined the potential for gender to further moderate the relationship between BMI and treatment efficacy. RESULTS: In the placebo controlled trial (N = 1,621), 21-mg patch was no more effective than placebo for assisting biochemically verified point prevalence abstinence up to 1 year after quitting for women with higher BMI, but appeared to be effective for men at normal or high BMI (gender × BMI beta = -0.22, p = .004). We did not find differential long-term cessation outcomes among male or female smokers in the 15-mg patch trial (n = 705). However, we observed significantly higher rates of early lapse among women with higher BMI treated with nicotine patch across both trials. CONCLUSION: These results suggest that increased BMI may affect the efficacy of nicotine patch on reducing risk of early lapse in women. Additional research is needed to explore mechanisms of risk for decreased efficacy of this commonly used cessation aid.
INTRODUCTION: Rates of obesity are higher among more dependent smokers and 37%-65% of smokers seeking cessation treatment are overweight or obese. Overweight or obese smokers may possess metabolic and neurobiological features that contribute to difficulty achieving cessation using front-line nicotine replacement products. Attention to factors that facilitate effective cessation treatment in this vulnerable population is needed to significantly reduce mortality risk among overweight and obese smokers. METHOD: This secondary analysis of 2 large trials of transdermal nicotine replacement in general medical practices evaluated the hypothesis that higher body mass index (BMI) would moderate the efficacy of the nicotine patch. We examined the potential for gender to further moderate the relationship between BMI and treatment efficacy. RESULTS: In the placebo controlled trial (N = 1,621), 21-mg patch was no more effective than placebo for assisting biochemically verified point prevalence abstinence up to 1 year after quitting for women with higher BMI, but appeared to be effective for men at normal or high BMI (gender × BMI beta = -0.22, p = .004). We did not find differential long-term cessation outcomes among male or female smokers in the 15-mg patch trial (n = 705). However, we observed significantly higher rates of early lapse among women with higher BMI treated with nicotine patch across both trials. CONCLUSION: These results suggest that increased BMI may affect the efficacy of nicotine patch on reducing risk of early lapse in women. Additional research is needed to explore mechanisms of risk for decreased efficacy of this commonly used cessation aid.
Authors: Terry Bush; Michele D Levine; Mona Deprey; Barbara Cerutti; Susan M Zbikowski; Tim McAfee; Lisa Mahoney; Laura Beebe Journal: J Smok Cessat Date: 2008-12-01
Authors: Megan E Piper; Tanya R Schlam; Jessica W Cook; Megan A Sheffer; Stevens S Smith; Wei-Yin Loh; Daniel M Bolt; Su-Young Kim; Jesse T Kaye; Kathryn R Hefner; Timothy B Baker Journal: Psychopharmacology (Berl) Date: 2011-03-18 Impact factor: 4.530
Authors: Saul Shiffman; Stuart G Ferguson; Chad J Gwaltney; Mark H Balabanis; William G Shadel Journal: Psychopharmacology (Berl) Date: 2005-11-01 Impact factor: 4.530
Authors: Paul Aveyard; Karen Brown; Cas Saunders; Avril Alexander; Elaine Johnstone; Marcus R Munafò; Mike Murphy Journal: Thorax Date: 2007-05-04 Impact factor: 9.139
Authors: Mohammad Siahpush; Gopal K Singh; Melissa Tibbits; Courtney A Pinard; Raees A Shaikh; Amy Yaroch Journal: Tob Control Date: 2013-04-10 Impact factor: 7.552
Authors: Robert West; A Eden Evins; Neal L Benowitz; Cristina Russ; Thomas McRae; David Lawrence; Lisa St Aubin; Alok Krishen; Melissa C Maravic; Robert M Anthenelli Journal: Addiction Date: 2018-03-30 Impact factor: 6.526